VCP-Eribulin |
Catalog No.GC37892 |
VCP-Eribulin se compose du lieur ADCs (VCP) et de l'Eribulin. L'éribuline est un inhibiteur mécanistiquement unique des microtubules pour le cancer. VCP-Eribulin est un médicament À base d'Eribulin pour les conjugués d'anticorps.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2130869-17-7
Sample solution is provided at 25 µL, 10mM.
VCP-Eribulin consists the ADCs linker (VCP) and Eribulin[1]. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. VCP-Eribulin is an Eribulin-based drug for antibody conjugates[1].
[1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1. [2]. Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505.
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *